Literature DB >> 12069182

Improved survival of TNF-deficient mice during the zymosan-induced multiple organ dysfunction syndrome.

Thomas J H Volman1, Thijs Hendriks, Albert A J Verhofstad, Bart-Jan Kullberg, R Jan A Goris.   

Abstract

The purpose of the study was to investigate the course of the zymosan-induced multiple organ dysfunction syndrome (MODS) in the absence of tumor necrosis factor (TNF) in a murine model. Tumor Necrosis Factor-alpha-lymphotoxin-a knockout (TNF/LT-/-) mice (n = 36) and wild-type (TNF/LT+/+) mice (n = 36) received 40 microg of lipopolysaccharide (LPS) intraperitoneally followed by zymosan at a dose of 1 mg/g body weight 6 days later (day 0). Animals were monitored daily for body weight and temperature and clinical symptoms. At day 22, most of the surviving mice were killed to examine organ weight and histology. A small number of animals were followed until day 48. In all animals, zymosan induced an acute sterile peritonitis phase followed by an apparent recovery. From day 8 onwards the TNF/LT+/+ mice entered a third-MODS-like-phase, characterized by loss of body weight, decreased body temperature, and significant mortality. At day 22, survival in the TNF/LT-/- mice (92%) was significantly (P = 0.01) higher than in the TNF/LT+/+ mice (60%). In addition, average body temperature and average relative (vs. weight at day 0) body weight were higher in the TNF/LT-/- mice than in the TNF/LT+/+ mice (35.9 degrees C and 100% vs. 33.3 degrees C and 84%, respectively). However, at this time point, surviving animals from both groups showed similar and significant organ damage, indicated by an increase in absolute and relative (vs body weight) weight of lung, spleen, and liver (liver only in the TNF/LT-/- mice). Moreover, histopathological examination of organs from the surviving animals showed a similar degree of microscopic damage in both groups. Interestingly, besides mononuclear cells, inflammatory infiltrates in lungs and livers of TNF/LT+/+ but not of TNF-/- mice contained neutrophils. In conclusion, TNF-deficient mice exhibit significantly improved morbidity and mortality during zymosan-induced MODS. However, the absence of TNF does not completely protect against MODS in this murine model.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12069182     DOI: 10.1097/00024382-200206000-00005

Source DB:  PubMed          Journal:  Shock        ISSN: 1073-2322            Impact factor:   3.454


  9 in total

1.  Pentoxifylline does not improve outcome in a murine model for the multiple-organ dysfunction syndrome.

Authors:  T J H Volman; R J A Goris; T Hendriks
Journal:  Intensive Care Med       Date:  2005-02-15       Impact factor: 17.440

2.  Blockade of nuclear factor-kappaB activation prevents hypodynamic shock and gastric hypoperfusion induced by endotoxin in anesthetized dogs.

Authors:  Chieko Mitaka; Yukio Hirata; Yutaka Narumi; Kuninori Yokoyama; Koshi Makita; Koichi Katsuyama; Takasuke Imai
Journal:  Intensive Care Med       Date:  2005-04-06       Impact factor: 17.440

3.  Hyperbaric oxygen therapy reduces the toll-like receptor signaling pathway in multiple organ failures.

Authors:  Barbara Rinaldi; Salvatore Cuzzocrea; Maria Donniacuo; Annalisa Capuano; Donatella Di Palma; Francesco Imperatore; Emanuela Mazzon; Rosanna Di Paola; Loredana Sodano; Francesco Rossi
Journal:  Intensive Care Med       Date:  2011-05-13       Impact factor: 17.440

4.  Evodiamine Inhibits Zymosan-Induced Inflammation In Vitro and In Vivo: Inactivation of NF-κB by Inhibiting IκBα Phosphorylation.

Authors:  Xia Fan; Jun-Yu Zhu; Yu Sun; Li Luo; Jun Yan; Xue Yang; Jing Yu; Wan-Qi Tang; Wei Ma; Hua-Ping Liang
Journal:  Inflammation       Date:  2017-06       Impact factor: 4.092

5.  The cyclopentenone prostaglandin 15-deoxydelta(12,14)-prostaglandin J2 attenuates the development of zymosan-induced shock.

Authors:  Stefania Marzocco; Rosanna Di Paola; Emanuela Mazzon; Tiziana Genovese; Domenico Britti; Aldo Pinto; Giuseppina Autore; Salvatore Cuzzocrea
Journal:  Intensive Care Med       Date:  2005-03-15       Impact factor: 17.440

6.  Role of PPAR-delta in the development of zymosan-induced multiple organ failure: an experiment mice study.

Authors:  Maria Galuppo; Rosanna Di Paola; Emanuela Mazzon; Tiziana Genovese; Concetta Crisafulli; Irene Paterniti; Elisabetta Cuzzocrea; Placido Bramanti; Amar Kapoor; Christoph Thiemermann; Salvatore Cuzzocrea
Journal:  J Inflamm (Lond)       Date:  2010-02-18       Impact factor: 4.981

7.  Protection by mTOR Inhibition on Zymosan-Induced Systemic Inflammatory Response and Oxidative/Nitrosative Stress: Contribution of mTOR/MEK1/ERK1/2/IKKβ/IκB-α/NF-κB Signalling Pathway.

Authors:  Seyhan Sahan-Firat; Meryem Temiz-Resitoglu; Demet Sinem Guden; Sefika Pinar Kucukkavruk; Bahar Tunctan; Ayse Nihal Sari; Zumrut Kocak; Kafait U Malik
Journal:  Inflammation       Date:  2018-02       Impact factor: 4.092

8.  Pyrrolidine dithiocarbamate attenuates the development of organ failure induced by zymosan in mice.

Authors:  Salvatore Cuzzocrea; Antonietta Rossi; Barbara Pisano; Rosanna Di Paola; Tiziana Genovese; Nimesh S A Patel; Elisabetta Cuzzocrea; Angela Ianaro; Lidia Sautebin; Francesco Fulia; Prabal K Chatterjee; Achille P Caputi; Christoph Thiemermann
Journal:  Intensive Care Med       Date:  2003-07-17       Impact factor: 17.440

9.  Tissue- and time-dependent upregulation of cytokine mRNA in a murine model for the multiple organ dysfunction syndrome.

Authors:  Thomas J H Volman; R Jan A Goris; Jos W M van der Meer; Thijs Hendriks
Journal:  Ann Surg       Date:  2004-07       Impact factor: 12.969

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.